PolidoroM.. CKD-MBD: un caso “resistente”.Giornale di Techniche Nefrologiche e Dialitiche2014; 26(4): 348–53.
2.
HolickM.F.. Vitamin D Deficiency.N Engl J Med2007; 357: 266–81.
3.
TeagardenD.L., MeadorK.J., LoringD.W.. Low vitamin D levels are common in patients with epilepsy.Epilepsy Res2014; 108(8): 1352–6.
4.
MenonB., HarinarayanC.V.. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism–a longitudinal study.Seizure2010; 19(3): 153–8.
5.
DussoA., ArcidiaconoM.V.. La carbamazepina antagonizza la soppressione di vitamina D-mediata dell'iperparatiroidismo secondario: patogenesi e possibilità terapeutiche.Giornale di Techniche Nefrologiche e Dialitiche2014; 26(4): 354–8.
6.
HolickM.F., GarabedianM.. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications.American Society for Bone and Mineral Research2006: 129–37.
7.
TominagaY., SatoK., TanakaY., NumanoM., UchidaK., TakagiH.. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure.Clin Nephrol1995; 44(Suppl 1): S42–7.
8.
IndridasonO.S., HeathH3rd, KhoslaS., YohayD.A., QuarlesL.D.. Non suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.Kidney Int1996; 50: 1663–7.
